Display options
Cite
Yamada M, Akita M, Nakagawa T, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. J Drug Assess. 2013;2(1):40-8doi: 10.3109/21556660.2013.792823.
Yamada, M., Akita, M., Nakagawa, T., Takahashi, N., Endo, A., & Yoshida, P. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. Journal of drug assessment, 2(1), 40-8. https://doi.org/10.3109/21556660.2013.792823
Yamada, Masanori, et al. "Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus." Journal of drug assessment vol. 2,1 (2013): 40-8. doi: https://doi.org/10.3109/21556660.2013.792823
Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. J Drug Assess. 2013 Apr 12;2(1):40-8. doi: 10.3109/21556660.2013.792823. eCollection 2013. PMID: 27536436; PMCID: PMC4937663.
Copy Download .nbib Format: NLM
Share it on

J Drug Assess. 2013 Apr 12;2(1):40-8. doi: 10.3109/21556660.2013.792823. eCollection 2013.

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.

Journal of drug assessment

Masanori Yamada, Mikio Akita, Tomofumi Nakagawa, Naoki Takahashi, Akira Endo, Pascal Yoshida

Affiliations

  1. Medicines Development, Japan Development & Medical Affairs Division, GlaxoSmithKline K.K., TokyoJapan.
  2. Clinical Pharmacology Department, Medicines Development, Japan Development & Medical Affairs Division, GlaxoSmithKline K.K., TokyoJapan.
  3. Biomedical Data Sciences Department, Japan Development & Medical Affairs Division, GlaxoSmithKline K.K., TokyoJapan.
  4. Clinical Safety & PMS, Japan Development & Medical Affairs Division, GlaxoSmithKline K.K., TokyoJapan.

PMID: 27536436 PMCID: PMC4937663 DOI: 10.3109/21556660.2013.792823

Abstract

OBJECTIVES: Belimumab, an anti-B lymphocyte stimulator (BLyS) human monoclonal antibody, was approved in the United States, Canada and European Union for the treatment of the patients with systemic lupus erythematosus (SLE). However, belimumab had not been evaluated in Japanese patients. The objectives of this study were to evaluate the safety and tolerability of belimumab in Japanese patients with SLE, as well as to investigate the pharmacokinetics (PK) and biological activity of belimumab in this population.

METHODS: A total of 12 Japanese patients were enrolled in a randomized, single-blind, placebo-controlled, dose-ascending design study. A dosing regimen of a single intravenous infusion over 1 hour of belimumab (1 mg/kg and 10 mg/kg) was employed. Patients were followed for 84 days after dosing to assess adverse events, pharmacokinetics, biomarkers and SLE disease activity.

CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier is NCT01381536.

RESULTS: Belimumab (1 mg/kg and 10 mg/kg) demonstrated a favorable clinical safety and tolerability profile in Japanese patients with SLE. The incidence of adverse events was similar among the two belimumab groups and placebo group. The PK profile of single-dose belimumab was approximately dose proportional, and the long terminal elimination half-life (12.4-15.7 days), low clearance (3.55-4.65 mL/day/kg), and small volume of distribution (76.2-80.1 mL/kg) were consistent with a fully humanized antibody. Effects of belimumab on B cells suggested biological activity effects expected as an inhibitor of BLyS.

LIMITATION: The small sample size and single dose design of this study prevent definitive conclusions regarding the safety, pharmacokinetics or pharmacodynamics of belimumab in a Japanese population being made.

CONCLUSIONS: The preliminary safety, PK profile, and observed biological activity of belimumab support further evaluation of its safety and efficacy in Japanese patient with SLE.

Keywords: Belimumab; Pharmacodynamics; Pharmacokinetics; Safety; Systemic lupus erythematosus

References

  1. Arthritis Rheum. 1997 Sep;40(9):1725 - PubMed
  2. Ann Rheum Dis. 2012 Nov;71(11):1833-8 - PubMed
  3. J Pharm Sci. 2004 Nov;93(11):2645-68 - PubMed
  4. Lancet. 2011 Feb 26;377(9767):721-31 - PubMed
  5. Arthritis Res Ther. 2008;10(5):R109 - PubMed
  6. Ann Rheum Dis. 2008 Feb;67(2):195-205 - PubMed
  7. Arthritis Rheum. 2008 Aug;58(8):2453-9 - PubMed
  8. J Clin Pharmacol. 2011 Aug;51(8):1237-40 - PubMed
  9. Arthritis Rheum. 2011 Dec;63(12):3918-30 - PubMed
  10. Arthritis Rheum. 2009 Sep 15;61(9):1168-78 - PubMed
  11. Arthritis Rheum. 2012 Jul;64(7):2328-37 - PubMed
  12. Clin Pharmacol Ther. 2008 Sep;84(3):287-94 - PubMed

Publication Types